Stochastic dynamics of leukemic cells under an intermittent targeted therapy

Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

(2009) D Rea et al.   LEUKEMIA

Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'

(2009) Nicolas André et al.   Nature clinical practice. Oncology

Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach

(2009) Nicola Pizzolato et al.   Open Physics

Stopping Treatment Can Reverse Acquired Resistance to Letrozole

(2008) G. J. Sabnis et al.   CANCER RESEARCH

Mathematical Modeling of Genesis and Treatment of Chronic Myeloid Leukemia

(2008) Matthias Horn et al.   CELLS TISSUES ORGANS

Stochastic model of the formation of cancer metastases via cancer stem cells

(2008) Vladimir P. Zhdanov   EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy

(2008) Giovanni Martinelli et al.   Nature clinical practice. Oncology

Intermittent androgen blockade should be regarded as standard therapy in prostate cancer

(2008) Bostjan Seruga et al.   Nature clinical practice. Oncology